ReviewGut and liver2018
Current Trends in the Management of Gastroesophageal Reflux Disease.
Review in Gut and liver, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 7 syntheses or guidelines pooled it, 214 citations in OpenAlex.
- Potassium-competitive Acid Blockers Versus Proton Pump Inhibitors for Erosive Esophagitis: A Systematic Review and Network Meta-analysis.Journal of neurogastroenterology and motility · 2026Pooled it
- A systematic review and meta-analysis of randomized controlled trials: the effect of potassium-competitive acid blockers on nighttime symptoms of gastroesophageal reflux disease.Esophagus : official journal of the Japan Esophageal Society · 2026Pooled it
- Peroral endoscopic myotomy compared to laparoscopic Heller myotomy and pneumatic dilation in the treatment of achalasia: a systematic review.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2024Pooled it
- Risk factors and 26-years worldwide prevalence of endoscopic erosive esophagitis from 1997 to 2022: a meta-analysis.Scientific reports · 2023Pooled it
- Efficacy of laparoscopic Toupet fundoplication compared to endoscopic and surgical procedures for GERD treatment: a randomized trials network meta-analysis.Langenbeck's archives of surgery · 2023Pooled it
- Thailand guideline 2020 for medical management of gastroesophageal reflux disease.Journal of gastroenterology and hepatology · 2022Guideline
- Prevalence and risk factors for gastroesophageal reflux disease in the Indian population: A meta-analysis and meta-regression study.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2021Pooled it
- Trial
- Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis.World journal of gastroenterology · 2022Trial
- Anti-Heartburn Effects of Sugar Cane Flour: A Double-Blind, Randomized, Placebo-Controlled Study.Nutrients · 2020Trial
- A gene therapy approach to prevent dilated intercellular space, a hallmark of gastroesophageal reflux disease.Gene therapy · 2026Article
- Real world clinical practice patterns in nocturnal GERD management: insights from nationwide RELIEF survey.BMC gastroenterology · 2026Article
- 2025 Focused Update of the Seoul Consensus on Gastroesophageal Reflux Disease: Evidence-based Recommendations on Acid Suppressive Therapy.Journal of neurogastroenterology and motility · 2026Review
- Retrosternal Burning and Its Endoscopic Associations: Findings from 5,561 Upper Gastrointestinal Endoscopies.Iranian journal of medical sciences · 2026Article
- Research progress in clinical utilization of HFrontiers in pharmacology · 2026Review
- Economic Impact of a Precision Nutrition Digital Therapeutic on Employer Health Costs: A Multi-Employer and Multi-Year Claims Analysis.Healthcare (Basel, Switzerland) · 2025Article
- Association of healthy lifestyle behaviors with incident gastroesophageal reflux disease in a large population-based prospective cohort.Preventive medicine reports · 2025Article
- Global, regional and national burdens of gastroesophageal reflux disease from 1990 to 2021 and projections to 2050: a finding from the global burden of disease study 2021.BMC public health · 2025Article
- Review
- Association of gastroesophageal reflux disease with small intestinal bacterial overgrowth: a case-control study.BMC gastroenterology · 2025Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroesophageal reflux disease (GERD) characterized by heartburn and/or regurgitation symptoms is one of the most common gastrointestinal disorders managed by gastroenterologists and primary care physicians. There has been an increase in GERD prevalence, particularly in North America and East Asia. Over the past three decades proton pump inhibitors (PPIs) have been the mainstay of medical therapy for GERD. However, recently there has been an increasing awareness amongst physicians and patients regarding the side effects of the PPI class of drugs. In addition, there has been a marked decline in the utilization of surgical fundoplication as well as a rise in the development of nonmedical therapeutic modalities for GERD. This review focuses on different management strategies for GERD, optimal management of refractory GERD with special focus on available endoluminal therapies and the future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.